- Academic Editor
Clinically assessing arterial stiffness is valuable because it aids in predicting future cardiovascular events. There are several methods for measuring arterial stiffness, including pulse wave velocity (PWV), augmentation index, and pulse pressure. Numerous studies have shown that these indicators of arterial stiffness possess prognostic value for various patient groups as well as the general population. In cross-sectional studies, arterial stiffness was also linked to organ damage indices. However, most studies related to arterial stiffness have relied on a single measurement. Taking multiple serial measurements of arterial stiffness offers several advantages. Through repeated assessments, one can confirm the variability of arterial stiffness and observe changes over time, which is beneficial for understanding its pathophysiology. Such repeated measurements are also invaluable in evaluating the efficacy of interventions aimed at improving arterial stiffness. However, caution is needed, as there is no standardized method for measuring arterial stiffness. For instance, with PWV, the values can be influenced by numerous external factors. Therefore, the external conditions during the measurement must be noted. It’s essential to recognize the pros and cons of repeated arterial stiffness measurements and integrate them effectively into clinical practice.
The stiffness of artery walls naturally increases as part of the aging process [1, 2]. However, this arterial stiffness is not solely the result of aging. Several other factors also contribute to its augmentation, such as a prolonged exposure to high blood pressure (BP), hyperglycemia, smoking, inflammation and reactive oxygen species [3, 4]. All these factors together lead to a more rigid arterial system, consequently impacting the overall cardiovascular health of an individual. This rise in arterial stiffness is a crucial factor closely associated with future cardiovascular events. It has been observed that individuals with stiffer arteries are at a heightened risk of cardiovascular incidents [5, 6]. In addition, arterial stiffness is also a strong predictor of potential target organ damage [7, 8, 9]. Thus, monitoring arterial stiffness is a useful tool for predicting future cardiovascular events, not only in specific patient groups who are already at risk [10, 11, 12, 13, 14, 15, 16] but also in the general population [17, 18, 19].
By periodically and repeatedly measuring the level of arterial stiffness at regular intervals, clinicians can obtain a more detailed and nuanced understanding of an individual’s cardiovascular health. This can inform a more comprehensive, proactive approach to disease prevention and management [11, 20, 21, 22]. However, most of the current research on arterial stiffness is based on a single measurement taken at a specific point in time, which may not provide a complete picture of the individual’s ongoing cardiovascular condition. Repeated measurements of arterial stiffness offer valuable data, but their use in clinical practice presents a unique set of challenges. Some of these issues include the logistical difficulties associated with frequent testing, patient compliance, and the variability in measurements due to multiple factors. These challenges may have hindered the progress of research in this area.
This review aims to explore the advantages and disadvantages of using repeated measurements of arterial stiffness as a tool in the field of cardiovascular disease (CVD). It will shed light on how these measurements can be effectively used, the obstacles to their implementation, and possible solutions to overcome these challenges. This deeper understanding of arterial stiffness and its implications will be vital in driving improvements in cardiovascular care.
There are several methods to measure arterial stiffness. The most commonly used method, both clinically and in research, is the measurement of pulse wave velocity (PWV) [23]. PWV measures the speed of the pulse wave traveling along the arterial wall. It operates on the principle that as arterial stiffness increases, the speed of the pulse wave increases correspondingly [24]. Generally, PWV is calculated by dividing the distance between two points by the time difference between the pulse wave arrivals at these points [23]. Several types of PWV exist, depending on the two points chosen for measurement. The most widely recognized types are carotid-femoral PWV (cfPWV) and brachial-ankle PWV (baPWV) [25]. Since cfPWV includes only elastic arteries, it is theoretically the most accurate indicator of central artery stiffness [26]. cfPWV has historically been the first method used and its prognostic value has been validated in numerous clinical studies. It is considered the gold standard for non-invasive measurements of arterial stiffness [26]. baPWV, a method developed in Japan following cfPWV, is primarily used in Asian populations [27]. Since baPWV incorporates muscular arteries, it is not as precise a measure of central artery stiffness as cfPWV [27]. However, it provides a more comprehensive representation of the heart’s total afterload [28]. Unlike cfPWV, which requires technical skill to locate the carotid and femoral arteries, baPWV measurement is more straightforward and convenient, as it only involves placing a BP cuff around the arm or leg. This convenience makes baPWV advantageous when measuring a large number of patients [4].
PWV is widely utilized due to its non-invasive nature and the relative ease with
which it can be measured. However, one of the biggest disadvantages of PWV is
that the PWV value is greatly affected by BP. As BP rises, the PWV value also
increases, so the BP value must be corrected or considered when interpreting the
PWV value [29]. To overcome these shortcomings of PWV, alternative indices like
Another method to assess arterial stiffness involves measuring parameters
related to wave reflection. As arterial stiffness increases, the velocity of
these reflected waves also increases, causing them to merge with the
forward-traveling wave sooner. This leads to an increase in systolic pressure (=
augmentation pressure (AP)) and a decrease in diastolic pressure, which in turn
results in a heightened pulse pressure (PP) [32, 33]. Thus, an elevation in AP
and PP can serve as indicators of arterial stiffness [33]. Augmentation index
(AIx) is calculated as the difference between the reflected and forward systolic
peaks (= AP), expressed as a percentage of the PP (= AP/PP
Arterial compliance and arterial stiffness can be assessed by observing changes
in arterial diameter during systole and diastole. These measurements can be made
using imaging technologies such as ultrasound, computed tomography, and magnetic
resonance imaging (MRI). MRI provides high-resolution images, allowing detailed
analysis of the arterial wall and its components. The ability to visualize and
quantify multiple parameters related to arterial structure and function enables a
more comprehensive assessment of arterial stiffness. MRI can measure aortic
distensibility (= change in aortic area/[aortic area at diastole
PWV, AP and PP can be assessed through invasive measurement of aortic pressure. This involves the insertion of a catheter directly into the aortic root to measure intra-arterial pressure. Although this method provides highly accurate results, it is invasive and is generally limited to patients who are already undergoing invasive procedures like coronary angiography [10, 36]. With technological advancements, it’s now possible to estimate central arterial pressure by analyzing the waveform of the radial artery. This method is known for its excellent accuracy and is becoming increasingly utilized in clinical practice [37, 38].
Previous studies have established a close association between increased arterial stiffness and organ damage. Specifically, it has been confirmed that patients with increased arterial stiffness exhibit a higher incidence of left ventricular hypertrophy [8], left ventricular diastolic dysfunction [7, 39], coronary artery stenosis [40], and cerebrovascular disease [41]. Furthermore, arterial stiffness has been found to be a powerful and reliable predictor of future cardiovascular events. The implications of this discovery are far-reaching, applying not only to the general population [17, 18, 19] but even extending to patients with certain diseases [10, 11, 12, 13, 14, 15, 16]. Further reinforcing these findings, a comprehensive meta-analysis of numerous studies has unequivocally reasserted the prognostic value of arterial stiffness in anticipating cardiovascular events [5, 6]. Intriguingly, it has been found that the predictive potential of arterial stiffness is independent of traditional cardiovascular risk factors. This includes well-established risk contributors such as hypertension, diabetes, obesity, and smoking habits. Such findings suggest the importance of arterial stiffness in stratifying cardiovascular risk across diverse patient cohorts.
Several reasons have been proposed to explain the heightened risk of organ damage and poor cardiovascular prognosis associated with increased arterial stiffness. Blood vessels that exhibit this heightened stiffness can’t properly buffer the pulsatile energy from the heart, which can lead to target organ damage [33]. Moreover, an increase in arterial stiffness accelerates the speed of the reflected wave, causing it to encounter the forward wave at an earlier stage. This interaction leads to a rise in systolic BP and a drop in diastolic BP. The ensuing increase in both systolic BP and PP can trigger left ventricular hypertrophy, which in turn promotes left ventricular diastolic dysfunction and subendocardial ischemia [4]. A decrease in diastolic BP can reduce coronary blood flow [32]. Additionally, an increased PP can disrupt the blood-brain barrier, potentially causing brain damage. Factors such as aging, high BP, inflammation, and oxidative stress often accompany increased arterial stiffness and can accelerate the progression of atherosclerosis [4].
Most studies on arterial stiffness have relied on a single measurement of the arterial stiffness index at a specific time point. However, data derived from repeated measurements of arterial stiffness can yield more informative insights. The process of taking serial measurements of arterial stiffness carries several significant advantages that can greatly benefit medical research and patient management. For instance, fluctuations in arterial stiffness over time can serve as early indicators of vascular diseases like atherosclerosis [42, 43], thus enabling timely interventions. Additionally, repeated measurements of arterial stiffness enable the identification of pathophysiology more clearly related to arterial stiffness, which may not be adequately understood through a single measurement [20, 44, 45, 46, 47, 48, 49]. Furthermore, through the serial measurement of arterial stiffness, physicians can evaluate the efficacy of therapeutic interventions on a patient’s arterial health [50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61]. A treatment that leads to a reduction in arterial stiffness often signals its effectiveness. Additionally, serial measurements of arterial stiffness can aid in stratifying the risk of future cardiovascular events in patients. This tool is invaluable for physicians as it allows them to identify individuals at high risk and make more informed decisions regarding their treatment plans. Finally, serial measurements can prove useful in tracking disease progression [20]. An increase in arterial stiffness may signify deteriorating health, while a decrease or stability in stiffness may indicate health improvement or maintenance of stability [43, 62]. Table 1 (Ref. [20, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66]) summarizes the results of several major studies related to serial measurement of arterial stiffness.
Source (year) | Study population | Number of subjects | Intervention | Time interval between the measurements | Measure of arterial stiffness | Main result |
Kim et al. (2023) [62] | Patients underwent PCI | 405 | No interventions | 1 month | baPWV | Increased baPWV/SBP was associated with worse clinical outcomes. |
Zhou et al. (2022) [54] | Adults with higher atherosclerotic risk | 820 | Statins | Mean 4.8 years | baPWV | Compared with non-statin users, statin users had significantly slower progression of baPWV. |
Nakamura et al. (2021) [53] | Patients with CAD | 323 | Optimal medical treatment | 2 years | baPWV | Improvement of baPWV was associated with better cardiovascular outcome. |
Rueangjaroen et al. (2021) [46] | Pregnant women | 335 | No intervention | Gestational age 11–14, 18–22, 28–32, and after 36 weeks | CAVI | Increased CAVI was associated with the development of preeclampsia and fetal growth restriction. |
Mandraffino et al. (2020) [59] | Patients with FH | 98 | PCSK-9 inhibitor or ezetimibe | 6 months | cfPWV | Add on therapy of PCSK-9 inhibitor or ezetimibe to statin therapy significantly reduced cfPWV. |
Toussaint et al. (2020) [55] | Patients with stage 3b or 4 CKD | 278 | Phosphate-lowering medication | 96 weeks | cfPWV | cfPWV was not changed by phosphate-lowering medication. |
Kim et al. (2020) [63] | Patients with preeclampsia | 37 | No intervention | 1 year | CAVI | CAVI was not changed at 1 year after preeclampsia. |
Reshetnik et al. (2020) [64] | ESRD patients | 54 | Dialysis | 7 days | aPWV | aPWV was not changed by dialysis. |
Jennings et al. (2019) [50] | Healthy subjects | 225 | Mediterranean-style diet | 1 year | cfPWV, AIx | cfPWV was not changed but AIx decreased by Mediterranean-style diet. |
Kadoya et al. (2018) [45] | General population | 306 | No intervention | 3 years | baPWV | Low sleep quality was associated with increased baPWV. |
Merlocco et al. (2017) [47] | Children and young adults with connective tissue disorders | 50 | No intervention | Median 3.9 years | CMR | There was a weak correlation between increased arterial stiffness and aortic root dilatation. |
Kong et al. (2017) [49] | Healthy subjects | 7154 | No intervention | 3 years | cfPWV | Increased cfPWV was associated with CKD development. |
Peyster et al. (2017) [44] | CKD patients | 2933 | No intervention | 0, 2, 4 years | cfPWV | cfPWV change was not associated with baseline levels of inflammatory markers. |
Yuan et al. (2016) [56] | Young male overweight adults | 20 | Swimming | 8 weeks | Carotid arterial stiffness decreased after exercise. | |
Ro et al. (2016) [51] | K-TPL recipients | 67 | K-TPL | 6 month, 1, 2 years | baPWV | baPWV was improved by K-TPL. |
Seetho et al. (2015) [57] | Patients with obesity and OSA | 52 | CPAP | Median 13.5 months | AIx | AIx was reduced by CPAP. |
Jochemsen et al. (2015) [48] | Patients with arterial disease | 526 | No intervention | Mean 4.1 years | CMR | Carotid artery stiffening was not associated with brain volumes or infarcts. |
Otsuka et al. (2014) [43] | Patients with CAD | 211 | No intervention | 6 months | CAVI | Persistent impairment of arterial stiffness was an independent risk factor of future CVD events. |
Oberoi et al. (2013) [42] | Patients with suspected CAD | 164 | No intervention | Mean 12 months | Aortic distensibility index by CT | The progression of aortic stiffness is associated with the progression of coronary atherosclerosis. |
AlGhatrif et al. (2013) [20] | General population | 777 | No intervention | 2~9 serial measurement between 1988 and 2013 | cfPWV | There was a steeper longitudinal increase of cfPWV in men than women. |
Kim et al. (2011) [60] | Patients with diabetes and hypertension | 47 | Valsartan | 12 weeks | cfPWV | Valsartan improved cfPWV. |
Phillips et al. (2010) [52] | Healthy male subjects | 28 | High-fat meal diet | 6 hours | AIx | AIx decreased by high-fat meal diet. |
Eryılmaz et al. (2010) [61] | Patients with OSA | 44 | CPAP | 6 months | Arterial elasticity indices | CPAP therapy improves arterial elasticity. |
Yoon et al. (2010) [65] | Healthy subjects | 13 | Resistance exercise | At baseline and 20 minutes after exercise | cfPWV, AIx | cfPWV and AIx were increased in after resistance exercise. |
Yokoyama et al. (2005) [58] | Patients with hyperlipidemia | 40 | Fluvastatin | 12 months | baPWV | Fluvastin decreased baPWV value. |
Rajzer et al. (2003) [66] | Hypertensive subjects | 118 | Amlodipine, losartan, quinapril | 0, 3, 6 months of medications | cfPWV | Only quinapril was associated with cfPWV reduction. |
PCI, percutaneous coronary intervention; CAD, coronary artery disease; FH, familial hypercholesterolemia; CKD, chronic kidney disease; ESRD, end-stage renal disease; K-TPL, kidney transplantation; OSA, obstructive sleep apnea; CPAP, Continuous Positive Airway Pressure; baPWV, brachial-ankle PWV; CAVI, cardio-ankle vascular index; cfPWV, carotid-femoral PWV; aPWV, arterial pulse wave velocity; AIx, Augmentation index; CMR, cardiac magnetic resonance; CT, computerized tomography; SBP, Spontaneous Bacteria Peritonitis; CVD, cardiovascular disease.
By undertaking serial measurements, clinicians can monitor the trajectory of arterial stiffness in individual patients [20, 67, 68, 69]. Such longitudinal assessments allow for detecting subtle changes that may precede overt symptoms or clinical manifestations of CVD [20, 68]. This proactive monitoring allows for timely interventions, such as early identification of a gradual rise in BP or incremental changes in blood glucose levels [69, 70]. Early detection opens the way for personalized therapeutic strategies encompassing lifestyle modifications, dietary changes, and pharmacological interventions, potentially halting or even reversing arterial deterioration [54, 56]. Moreover, serial measurements aid in evaluating the efficacy of treatments [58, 60, 61, 66]. By monitoring the parameters of arterial stiffness, clinicians can determine the therapeutic efficacy of a chosen strategy and make necessary adjustments. Additionally, these repetitive assessments enable personalized patient care. As every individual responds differently to treatments, frequent measurements allow tailoring therapy based on real-time data, leading to optimal outcomes. Finally, understanding the progression of CVD through serial measurements provides valuable prognostic information. Patients showing consistent improvements in measured parameters have a better prognosis than those with deteriorating or fluctuating values [43, 62].
Although serial measurement of arterial stiffness has become an invaluable tool in both cardiovascular research and clinical practice, it has several shortcomings. Various devices and techniques, such as tonometry, Doppler, and oscillometry, can produce slightly different arterial stiffness values [23]. Furthermore, the measurements can be operator-dependent, introducing potential variability. Arterial stiffness is subject to fluctuations based on factors like circadian rhythms, dietary intake, stress, and other transient influences, affecting the timing and consistency of measurements [26]. Especially with PWV, the values are sensitive to current BP [29]. Distinguishing between inherent changes in the arterial wall and just BP alterations can be challenging. Additionally, arterial stiffness is not uniform throughout the body. For instance, while cfPWV evaluates aortic stiffness, it may not accurately represent the stiffness in peripheral or coronary arteries. Standardized values for arterial stiffness across diverse populations are lacking, complicating the establishment of definitive risk thresholds. Moreover, the cost and accessibility of regular measurements can be prohibitive, limiting their widespread use in some clinical settings. Factors like arrhythmias or pronounced obesity can hinder the acquisition of precise PWV measurements. Therefore, while serial measurements of arterial stiffness provide significant insights, their interpretation requires careful consideration of the aforementioned constraints. To maximize their efficacy in cardiovascular risk management, these measurements should be incorporated alongside other clinical and investigatory data.
The strengths and limitations of serial measurement of arterial stiffness are summarized in Table 2.
Strengths | Limitations |
Monitoring the trajectory | Device and technique variability |
Allows for timely interventions | Operator-dependence |
Personalized therapeutic strategies | Sensitivity to many clinical factors at the time of measurement |
Evaluating efficacy of treatments | Lack of standardized values across populations |
Provides valuable prognostic information | Cost and accessibility |
Serial measurements of arterial stiffness significantly impact the management and prognosis of CVD by offering a comprehensive, evolving view of cardiovascular health, thereby guiding effective interventions and improving patient outcomes. However, it is essential to note that while these serial measurements are insightful, they must be interpreted with their limitations in mind. To maximize their effectiveness in cardiovascular risk management, it is beneficial to incorporate these measurements alongside other clinical and research data.
HLK created the overall flow and outline of this review article, wrote and revised the manuscript. The single author was responsible for the entire preparation of this manuscript.
Not applicable.
Not applicable.
This research received no external funding.
The author declares no conflict of interest. Hack-Lyoung Kim is serving as Guest Editor of this journal. We declare that Hack-Lyoung Kim had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Salvatore De Rosa.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.